www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Metabolism and Endocrinology
All latest versions
3 December 2024
4 June 2024
5 December 2023
6 June 2023
7 December 2022
7 June 2022
7 December 2021
8 June 2021
8 December 2020
10 June 2020
10 December 2019
12 June 2019
13 December 2018
12 June 2018
9 January 2018
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by publication date
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
Diabetes
Canagliflozine
IND
Dasiglucagon
Deudomperidone
Empagliflozine / metformine
IND
Insulin icodec
Insulin icodec / semaglutide
Regulatoire T-cellen (TREGS)
Teplizumab
Eye disorders
Mercaptamine
IND
Liver diseases
Arachidyl amido cholanoic acid
Elafibranor
Maralixibat
Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.
Extension of indication to include treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients 3 months of age and older
IND
Obeticholic acid
Odevixibat
IND
Resmetirom
Seladelpar
Metabolic diseases
Avalglucosidase alfa
Cipaglucosidase alfa
Dasiglucagon
IND
Eliglustat
IND
Elinzanetant
Encaleret
Fezolinetant
Govorestat
Patients with Classic Galactosaemia aged 2 to 65 years.
Sorbitol dehydrogenase deficiency
Leriglitazone
Liraglutide
IND
N-Acetyl-L-Leucine
Nedosiran
Olezarsen
Paltusotine
Pegunigalsidase alfa
Plozasiran
RGX-111
RGX-121
Rebisufligene etisparvovec
Relacorilant
Sepiapterin
Somapacitan
Somatrogon
IND
Sparsentan
Tiomolibdate choline
Other metabolism and Endocrinology
Alpelisib
Autologous human chondrocytes in vitro expanded
Copper histidine
Linzagolix
IND
Navepegritide
Pegzilarginase
Relugolix / estradiol / norethisterone acetaat
IND
Semaglutide
For weight management in people with obesity or who are overweight and have other related conditions.
Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adolescents ages 12 years and above with obesity and body weight above 60 kg. Treatment with Wegovy should be discontinued and re-evaluated if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose.
IND
Extension of indication to include risk reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and BMI ≥27 kg/m2.
IND
Op dit moment heeft oraal semaglutide reeds een indicatie voor diabetes. De aan te vragen indicatie uitbreiding zal slaan op het behandelen van obesitas.
IND
Setmelanotide
IND
Setrusumab
Tirzepatide
IND
Unknown
Mirabegron
IND
Olezarsen
Vibegron
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
Over de Horizonscan
About the Horizon Scan
Nederlands
English